| P/E (FY) | — | Sales (TTM) | $0 |
| Earnings (TTM) | -$60.8M | ROE | −63.84% |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $33.0M | Trading Days | 210 |
| 52W High | 3.23 |
| 52W Low | 0.69 |
| % Off High | −69.97% |
| YTD | −26.52% |
| Ann. Volatility (1Y) | 84.14% | Ann. Volatility (3Y) | 84.14% |
| Sharpe (1Y) | −1.26 | Sharpe (3Y) | −1.26 |
| Max Drawdown (1Y) | −76.66% | Max Drawdown (3Y) | −76.66% |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| NNVC | NANOVIRICIDES, INC. | $34.9M | — |
| SER | Serina Therapeutics, Inc. | $31.0M | — |
| MIRA | MIRA PHARMACEUTICALS, INC. | $35.3M | — |
| BCTX | BriaCell Therapeutics Corp. | $30.2M | — |
| GRCE | Grace Therapeutics, Inc. | $36.6M | — |
| HYPD | HYPERION DEFI, INC. | $36.7M | — |
| LTRN | Lantern Pharma Inc. | $29.4M | — |
| FBLG | FibroBiologics, Inc. | $29.0M | — |
| PDSB | PDS Biotechnology Corp | $38.5M | — |
| KYNB | KYNTRA BIO, INC. | $28.2M | 0.2 |
| ABVC | ABVC BIOPHARMA, INC. | $27.6M |
| ATNM | Actinium Pharmaceuticals, Inc. | $27.2M | — |
